TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05132985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg 1tt(Take 1 tablet 3 times a day) orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 (IV，Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 (IV, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 (IV, Q3W)
Study: NCT06398587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tumor biopsy
Study: NCT06203002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX9211 (blinded)
Description: LX9211 (blinded) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX9211 (blinded)
Description: LX9211 (blinded) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX9211 (blinded)
Description: LX9211 (blinded) tablets
Study: NCT06357221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetaphil
Description: Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
Study: NCT06500741

Intervention type: OTHER
Intervention: No Intervention
Description: No investigational drug will be administered to participants in this study.
Study: NCT05222139

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccination
Description: Monitoring COVID-19 vaccination
Study: NCT05995704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Peptide analogue of GLP-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to apraglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen mixed with a liquid meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen mixed with a liquid meal
Study: NCT05149196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted hemodynamic management
Description: During anesthesia, hemodynamic managements include active hydration (\>10 ml/kg/h), use of inotropes (dobutamine), and forced diuresis; the targets are to maintain pulse pressure variation \<9%, mean arterial pressure ≥85 mmHg, and urine output \>200 ml/h (3ml/kg/h).~During the first 48 hours after surgery, systolic blood pressure is maintained ≥110 mmHg or within 20% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or vasoactive infusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: During anesthesia, hemodynamic managements are conducted according to routine practice and usually include fluid infusion at a rate of 6-8 ml/kg/h without inotropics; the targets are to maintain mean arterial pressure ≥60 mmHg and urine output \>0.5 ml/kg/h.~During the first 48 hours after surgery, hemodynamic management is performed according to routine practice.
Study: NCT05381831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NatestoTM
Description: Administering daily intranasal testosterone, Natesto nasal gel is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone
Study: NCT03652909

Intervention type: DEVICE
Intervention: Ascending Hearing Technologies device
Description: Personal Sound Amplification Device
Study: NCT06117189

Intervention type: OTHER
Intervention: Questionnaire
Description: Oral Health Impact Daily Life questionnaire including 7 domains (eating, speaking, appearance, social, psychological, health, and finance) and 16 questions regarding perceived intensity
Study: NCT05233046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Mental health counseling
Description: Nutrition and Mental health counseling with a standardized format included in each session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Mental health counseling with Nourish Carolina
Description: Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
Study: NCT06378827

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
Study: NCT05700461

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Implantable Microdevice (IMD)
Description: Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib.
Study: NCT06398587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05318365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
Study: NCT06376656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The cognitive stimulation will comprise of psychoeducation, videogaming, book club and technology training workshop sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between psychoeducation, videogaming, book club and technology training workshop sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The cognitive stimulation will comprise of psychoeducation, videogaming, book club and technology training workshop sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between psychoeducation, videogaming, book club and technology training workshop sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The physical activity intervention will comprise of walking, Zumba, resistance exercise and aerobics sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between walking, Zumba, resistance exercise and aerobics sessions until the end of intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The physical activity intervention will comprise of walking, Zumba, resistance exercise and aerobics sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between walking, Zumba, resistance exercise and aerobics sessions until the end of intervention period.
Study: NCT04736589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrotinib
Description: Oral 400mg, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
Study: NCT04131374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence Therapy
Description: Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
Study: NCT05632874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxing breathing exercise
Description: Kumbhaka Pranayama, Sama Vritti Pranayama and box breathing breathing techniques will be applied to the patients.
Study: NCT06144918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-100 Ophthalmic Emulsion, 0.5%
Description: 0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-100 Ophthalmic Emulsion, 1.0%
Description: 1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SBI-100 Ophthalmic Emulsion, Placebo
Description: Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
Study: NCT05632744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CG-100 Intraluminal Bypass Device
Description: Subjects will be treated with the CG-100 Intraluminal Bypass Device
Study: NCT05287360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
Study: NCT06228755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Medicine Group Visit
Description: Integrative Medicine Group Visit (IMGV) is a 9-week group visit series co-facilitated by a billing primary care provider and a trained co-facilitator (such as a behavioral health provider, mindfulness instructor, or yoga teacher). The IMGV will be delivered virtually over a secure telehealth platform for 2 hours weekly. The IMGV curriculum focuses on principles of mindfulness-based stress reduction, and includes patient education on pain, insomnia, nutrition, yoga, depression, self-massage, and self-acupressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Strategies
Description: Package includes:~* Patient strategies will include an orientation session to introduce patients to the IMGV model.~* Provider strategies include training in delivery of IMGV with continuing education credits. Training may be delivered on-line or in-person. Ongoing coaching in the first year of IMGV implementation will also be offered to providers leading IMGV, to increase self-efficacy to deliver the curriculum, and enhance fidelity.
Study: NCT06108661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Moist heat therapy for 10 minutes for 3 times per week (alternatively) for 2 weeks.~TENS was applied for 15 minutes, 3 times per week (alternatively) for 2 weeks. Stretching protocol for deep lumbar spinal muscles was employed. The frequency was 3 times per week (alternatively) for 2 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Moist heat therapy for 10 minutes for 3 times per week (alternatively) for 2 weeks.~TENS was applied for 15 minutes, 3 times per week (alternatively) for 2 weeks. Stretching protocol for deep lumbar spinal muscles was employed. The frequency was 3 times per week (alternatively) for 2 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slump Stretching
Description: Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ELDOA
Description: ELDOA will be performed as per the tolerance of the patient (Max hold time=60sec) for 2 weeks (alternatively). For L4/L5 spinal segment patient sits on the floor, arms at the side legs relaxed.~For L5/S1 segment the patient lies on his or her side with torso perpendicular to a wall with the sitz bone pressing into the wall. The patient swing the legs up so that he or she is lying on his or her back with the legs perpendicular up the wall and the sitz bone pressing into the wall. The arms are lying by the sides.
Study: NCT06110377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)
Description: After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MMP (INJECTIONS WITH A TATTOO MACHINE)
Description: After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
Study: NCT06221319

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sacral erectör spinae plane group
Description: sacral erectör spinae plane will be applied to patients in Group S
Study: NCT05663983

Intervention type: BEHAVIORAL
Intervention: Description of therapeutical results
Description: Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
Study: NCT05047523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Administered as an oral tablet.
Study: NCT06038630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized Xe129
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
Study: NCT04334538

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-RUTF
Description: Children will receive approximately 175 kcal/kg/d of standard ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat RUTF
Description: Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
Study: NCT04719832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294 (Depemokimab)
Description: GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as a normal saline using a pre-filled syringe.
Study: NCT05325710

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study nurse intervention
Description: Contact everay 4 months with a dedicated study nurse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study nurse intervention
Description: Contact everay 4 months with a dedicated study nurse
Study: NCT06038630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized Xe129
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized Xe129
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Administration
Description: Oxygen administration
Study: NCT04334109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Diabetes Self-Management Education and Support
Description: Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Self-Management Education and Support
Description: Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
Study: NCT06123182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: During the audio recorded guided imagery exercise participants will be asked to think in detail of a future (6 months to a year) where they have made healthy choices regarding physical activity and are physically active.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: During the audio recorded guided imagery exercise participants will be asked to think in detail of a future (6 months to a year) where they have made healthy choices regarding physical activity and are physically active.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Episodic Recent Thinking
Description: During the audio recorded guided imagery exercise participants will be asked to think about a routine weekly activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Recent Thinking
Description: During the audio recorded guided imagery exercise participants will be asked to think about a routine weekly activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affective Imagery
Description: During the audio recorded guided imagery exercise participants will be asked to think in detail about the positive outcomes and sensations associated with an exercise bout.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affective Imagery
Description: During the audio recorded guided imagery exercise participants will be asked to think in detail about the positive outcomes and sensations associated with an exercise bout.
Study: NCT05047523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
Study: NCT05651646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm (STIMFIX)
Description: This is a single-arm prospective multicenter clinical study recruiting 50 subjects who are already undergoing a spinal cord stimulator trial for chronic back pain secondary to failed back surgical syndrome. Each patient who is recruited for spinal cord stimulator trial for their low back pain is informed about the traditional method of managing the leads and the trail lead anchoring system. If the patient agrees for the Stimfix trail lead anchoring clips StimfixTM, then informed consent is taken for anchoring clips usage during the spinal cord stimulator trail.
Study: NCT05117970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG-based Screening Tool
Description: Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
Study: NCT04987281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Solution
Description: Given via injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Bronchoscopy
Description: Undergo bronchoscopy using Ion robotic bronchoscope